ADHD Medication, Pregnancy and the Postpartum Period

Women who take ADHD medication and are pregnant, or planning to be, face a decision with incomplete information on both sides. Stopping medication has consequences. So might continuing it. This page reports what the main studies and FDA labels say and explains why they do not produce a single answer. It is general information. Do not start, stop or change a medication because of it.

Why there is no simple yes or no

Pregnant women are excluded from almost all medication trials, so the evidence comes from observational studies of insurance and health registers. Those studies can show whether an outcome is more common among women who filled prescriptions. They cannot fully separate the effect of the drug from the effect of the condition, other medications, smoking or other differences between women who continue treatment and those who do not.

FDA labels reflect that uncertainty. The label for one long-acting amphetamine product carries the summary statement that it may cause fetal harm, while also stating that published studies have not identified a drug-associated risk of major birth defects or miscarriage.

What studies show about birth defects

The largest study was published in JAMA Psychiatry in 2018. It examined 1.8 million pregnancies among women insured by US Medicaid and checked its findings against 2.56 million pregnancies in five Nordic countries. It looked at prescriptions filled in the first trimester.

A relative risk of 1.0 means no difference. The authors described the methylphenidate result as a small increase in the risk of cardiac malformations. To put a relative risk of 1.28 in scale: in the US data, heart defects were diagnosed in about 12.7 of every 1,000 infants not exposed to stimulants.

FDA labels are consistent with this. The methylphenidate label reviewed for this page states that published studies and postmarketing reports have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes, and adds that there may be risks to the fetus associated with stimulant use in pregnancy.

Other pregnancy outcomes

A 2017 study in Obstetrics and Gynecology used US Medicaid data from 2000 to 2010 to look at placenta-related complications. It compared about 4,800 pregnancies exposed to stimulants in early pregnancy with 1.46 million unexposed pregnancies.

• Preeclampsia: adjusted risk ratio 1.29. The baseline risk among unexposed women was 3.7%.
• Preterm birth: 1.06 for early-pregnancy use, not statistically significant. Among women who continued stimulants into the second half of pregnancy, compared with those who stopped, the ratio was 1.30. The baseline risk was 11.2%.
• Placental abruption and small size for gestational age: no significant association.
• Atomoxetine, a non-stimulant, was not associated with these outcomes, in a much smaller group of 453 pregnancies.

The authors concluded that the absolute increases in risk are small and that women with significant ADHD should not be counseled to suspend treatment on the basis of these findings.

The amphetamine label states that infants born to mothers taking amphetamines have an increased risk of premature delivery and low birth weight, and advises monitoring newborns for withdrawal symptoms such as feeding difficulties, irritability and excessive drowsiness.

For non-stimulants the data are thinner. The atomoxetine label says available published studies are insufficient to establish whether there is a drug-associated risk of major birth defects, miscarriage or other adverse outcomes.

What this page does not cover

Long-term child development after exposure in pregnancy was not verified against primary studies for this guide, so no claim is made about it here. The same applies to newer medications approved in 2026.

The other side: what stopping can cost

The risks of untreated ADHD in pregnancy have not been measured as carefully as the risks of medication, and this guide found no figure to cite. The considerations a prescriber raises are practical ones: the ability to work, drive safely, keep appointments, manage money and stay on top of prenatal care, along with how severe symptoms were before treatment and whether depression or anxiety is also present.

That is why the decision differs from one woman to the next. A woman whose symptoms are mild off medication is in a different position from one who has lost jobs or had car accidents without it. Options that clinicians discuss include continuing, changing to a different medication, pausing for part or all of the pregnancy, and strengthening non-drug supports. Each has trade-offs, and none is right for everyone.

Breastfeeding and the postpartum period

Labels differ by drug.

• The amphetamine label states that amphetamine is present in human milk, that there are no reports of adverse effects on the breastfed infant, that long-term effects are unknown, and that breastfeeding is not recommended during treatment.
• The methylphenidate label reports, from milk samples of seven mothers, much lower infant exposure, no reported adverse effects on the infant and no effects on milk production. It says the benefits of breastfeeding should be weighed with the mother's need for the medication, and that breastfed infants should be monitored for agitation, insomnia, poor appetite and reduced weight gain.

Both statements rest on very small numbers. The choice involves the pediatrician as well as the prescriber.

The weeks after delivery bring broken sleep and a sharp rise in demands on planning and memory, which can make ADHD symptoms harder to manage regardless of medication. Depression can also occur around childbirth. Low mood, hopelessness or frightening thoughts after a birth warrant a prompt call to a clinician. For thoughts of self-harm, call or text 988 at any hour. See ADHD and depression in adults.

Who to talk to in New York, and when

The best time for this conversation is before conception. The next best is as soon as a pregnancy is known.

• Your ADHD prescriber, for the history of how you function on and off medication and the options.
• Your obstetrician or midwife, for blood pressure monitoring and the overall pregnancy plan. Make sure each knows what the other has advised.
• Your pediatrician, for questions about breastfeeding.

New York State funds Project TEACH, a psychiatry access program that includes perinatal mental health. Its consultation line connects maternal health and primary care clinicians with a reproductive psychiatrist. It is a service for clinicians. Patients do not call it, and it does not provide ADHD care. If your obstetric clinician is unsure about an ADHD medication, you can ask whether they have considered a Project TEACH consultation.

FDA labels also mention a national pregnancy registry for ADHD medications that collects outcome information. Your clinician can tell you about enrolling.

Questions to bring

• What happened to my functioning the last time I was off medication?
• What do studies show for the specific medication I take?
• If I continue, what extra monitoring would you do?
• If I pause, what is the plan if things go badly, and when would I restart?
• What do you advise about breastfeeding on this medication?

The practice's treatment page describes how medication decisions are reviewed, and treatment without medication covers non-drug approaches. Prescription logistics matter more when plans change at short notice, so the comparison to read next is New York's rules for ADHD stimulant prescriptions.